Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
Property of [COMPANY_004] Consumer Healthcare
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of [COMPANY_004]
Template Version Effective: 22-Jun-2017
Page 1 of 56CLINICAL PROTOCOL
A single dose, open label, randomized scintigraphic study 
to investigate the gastrointestinal behavior of 2 triple 
combination products (Acetaminophen, Phenylephrine and 
Dextromethorphan) in healthy male volunteers
Compound Name:  [CONTACT_914845] & 
Cough powder for oral solution
Theraflu ExpressMax Daytime Severe 
Cold and Cough Caplets
[LOCATION_002] (US) Investigational 
New Drug (IND) Number:N/A
European Clinical Trials Database 
(EudraCT) Number:NA
Other Regulatory Agency Identified 
Number:NA
Protocol Number: 208821
Phase:I

T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: 2 2-J u n- 2 0 1 7 
Pa ge 2 of 5 6 S p o n s or i nf or m ati o n 
S p o ns or Le g al Re gistere d A d dress Gl a x o S mit h Kli ne Rese arc h & De vel o p me nt 
Li mite d 
[ADDRESS_1285819] Ge or ge’s A ve n ue, We y bri d ge 
S urre y, K T [ADDRESS_1285820] 
Gla x o S mit h Kli ne C o ns u mer Healt hcare 
N o vartis C o ns u mer Healt h S. A. 
R o ute de l’ Etraz 2, 1 2 6 9 N y o n 
S witzerla n d P P D 
P P D 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 3 of 56Document History
Document Version Date Summary of Changes 
Clinical Protocol, v2.0
(Amendment 1)25-January-2018Definition of Medical History 
added as a footnote to Table 1-1.
Clarification made to the 
following sections to ensure 
consistency that AEs are collected 
from Informed Consent.
1. Section 6.2
2. Section 6.2.2
3. Section 6.2.1 
4. Section 7.2.2
5. Section 8.2.1
Clarification added to Section 
7.2.2 that the cardiovascular 
system will be included in the 
physical examination.
Correction of ‘tobacco’ spelling in 
Section 6.1
Clarification in Section 7.2.7 that 
CRF will capture both results and 
clinically significant findings of 
ECG’s 
Clinical Protocol, v1.0
(Original Protocol)12-December-2017 Not applicable (N/A)
Amendments incorporate all revisions to date, including amendments made at the request of 
country health authorities, institutional review boards/ethics committees (IRBs/ECs), etc.  
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: 2 2-J u n- 2 0 1 7 
Pa ge 4 of 5 6 P RI N CI P A L I N V E S TI G A T O R P R O T O C O L A G R E E M E N T P A G E 
I c o nfir m a gree me nt t o c o n d uct t he st u d y i n c o m plia nce wit h t he pr ot oc ol a n d a n y 
a me n d me nts a n d acc or di n g t o t he c urre nt I C H G C P g ui deli nes. 
I ac k n o wle d ge t hat I a m res p o nsi ble f or o verall st u d y c o n d uct. I a gree t o pers o nall y 
c o n d uct or s u per vise t he descri be d st u d y. 
I a gree t o e ns ure t hat all ass ociates, c ollea g ues a n d e m pl o yees assisti n g i n t he c o n d uct of 
t he st u d y are i nf or me d a b o ut t heir o bli gati o ns. Mec ha nis ms are i n place t o e ns ure site staff 
recei ves all a p pr o priate i nf or mati o n t hr o u g h o ut t he st u d y. 
I a gree t o c o n d uct t his st u d y i n f ull c o nf or ma nce wit h t he la ws a n d re g ulati o ns of t he 
c o u ntr y i n w hic h t he researc h is c o n d ucte d a n d t he Declarati o n of Helsi n ki. 
I n vesti gat or Na me: Walter J. D oll 
I n vesti gat or Q ualificati o ns: P h. D., R. P h. 
I n vesti gat or Si g nat ure: 
Date of Si g nat ure/ A gree me nt: 
D D/ M M M/ Y Y Y Y P P D 
P P D 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285821] of tables.........................................................................................................................9
SCHEDULE OF ACTIVITIES .........................................................................................10
1 INTRODUCTION .............................................................................................................12
1.1 Mechanism of Action/Indication ...........................................................................[ADDRESS_1285822] SELECTION....................................................................................................14
4.1 Inclusion Criteria....................................................................................................15
4.2 Exclusion Criteria ..................................................................................................15
4.3 Randomization Criteria..........................................................................................17
4.4 Lifestyle Guidelines ...............................................................................................17
4.4.1 Meals and Dietary Restrictions .............................................................17
4.4.2 Alcohol, Caffeine and Tobacco.............................................................18
4.4.3 Activity..................................................................................................18
4.4.4 Contraception ........................................................................................18
4.5 Screen Failures.......................................................................................................19
4.6 Sponsor’s Qualified Medical Personnel.................................................................20
5 STUDY TREATMENTS...................................................................................................20
5.1 Blinding and Allocation to Treatment/Randomization..........................................[ADDRESS_1285823] Supplies ...................................24
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 6 of 565.8 Concomitant Treatment(s) .....................................................................................25
5.9 Rescue Medication.................................................................................................25
6 STUDY PROCEDURES ...................................................................................................25
6.1 Screening................................................................................................................25
6.2 Study Period 1........................................................................................................26
6.2.1 Visit 2: Day -1 .......................................................................................26
6.2.2 Visit 2: Day 1.........................................................................................[ADDRESS_1285824] 
REPORTING.....................................................................................................................34
8.1 Definitions of Adverse Events and Serious Adverse Events .................................34
8.1.1 Adverse Event .......................................................................................34
8.1.2 Serious Adverse Event ..........................................................................35
8.2 Reporting Period ....................................................................................................36
8.2.1 Adverse Event .......................................................................................36
8.2.2 Serious Adverse Event ..........................................................................37
8.3 Reporting Procedures.............................................................................................37
8.3.1 Adverse Event .......................................................................................38
8.3.2 Serious Adverse Event ..........................................................................38
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 7 of 568.3.3 Sponsor’s Reporting Requirements to Regulatory Authorities and 
Ethics Committees.................................................................................39
8.4 Evaluating Adverse Events and Serious Adverse Events ......................................39
8.4.1 Severity Assessment..............................................................................39
8.4.2 Causality Assessment ............................................................................40
8.5 Withdrawal Due to an Adverse Event and Serious Adverse Events......................40
8.6 Pregnancy...............................................................................................................40
8.6.1 Time period for collecting pregnancy information ...............................40
8.6.2 Action to be taken if pregnancy occurs .................................................41
8.7 Follow-up of Adverse Events and Serious Adverse Events ..................................41
9 DATA MANAGEMENT ..................................................................................................42
9.1 Source Documents/ Data........................................................................................[ADDRESS_1285825]/ Ethics Committee.....................................[ADDRESS_1285826] Recruitment ..............................................................................48
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 8 of 5611.3.5 Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP ...............................................................................................48
11.4 Posting of Information on Publicly Available Clinical Trial Registers.................48
11.5 Provision of Study Results to Investigators ...........................................................49
11.6 Records Retention..................................................................................................49
11.7 Conditions for Terminating the Study ...................................................................50
11.8 Definition of Study End/ End of Study..................................................................50
12 REFERENCES ..................................................................................................................50
13 APPENDIX........................................................................................................................52
13.1 RADIATION DOSIMETRY .................................................................................52
13.2 RADIOLABELING PROCEDURE ......................................................................53
13.3 ABBREVIATION..................................................................................................54
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285827] of tables
Table 1-1 Schedule of Activities............................................................................10
Table 7-1 Laboratory Tests....................................................................................30
Table 7-2 Blood Volume .......................................................................................34
Table 13-1 Abbreviation..........................................................................................54
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 10 of 56SCHEDULE OF ACTIVITIES
The schedule of activities table provides an overview of the protocol visits and procedures.  
The investigator may schedule visits (unplanned visits) in addition to those listed on the 
schedule of activities, in order to conduct evaluations or assessments required to protect the 
well-being of the subject.
Table 1-1 Schedule of Activities
Screening Study Period 1
Visit 1 Visit 2Procedure/Assessment
Day -21 to Day -2 Day -1 Day 1
Informed consent X
Inclusion/Exclusion criteria X X
Medical history /smoking 
historyhX X
Demographics X
Prior medications X X
Physical examination XcXcXc
Laboratory tests X Xd
Urine drug test X X
Height & weight X Xe
Breath Alcohol test X X
Urine Cotinine test X X
ECG X
Scintigraphic imagingaX
Vital signs 
(BP, PR, RR, oral 
temperature)XfXfXf
MealsbX X
Randomization X
Study treatment 
administrationX
Concomitant treatments X X X
Adverse eventsgX X X
Study conclusion X
Abbreviations:  ECG = electrocardiogram; BP = blood pressure; PR = pulse rate, RR = respi[INVESTIGATOR_914813] [ADDRESS_1285828]-dose.
c Full physical examination, on screening, on day -1, and brief physical examination on day 1 before randomization 
and another brief physical examination before discharge
dAfter final scintigraphic image is taken prior to dinner.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 11 of 56e Only weight.
f Vital signs that will be performed at visit 1 and visit 2 (day -1): BP, RR PR and oral temperature.  At visit 2 (day 
1) vital signs that will be performed are only BP and PR and they will be done before randomization and after the 
last scintigraphic image.
g AEs (serious and non-serious) will be collected from the time the subject has signed the informed consent form 
until [ADDRESS_1285829].
h Medical History recorded will be any existing or resolved condition that started prior to Informed Consent. 
Changes in medical history will be assessed at visit 2 (day-1)
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285830] frequent human illnesses worldwide (Gwaltney 1994) and, 
although no cure exists, symptoms are treatable. Cold remedies and multi-symptom drug 
combinations are available in a variety of formats, including a hot drink.  Hot drink remedies 
are associated with greater comfort and provide active ingredients in solution. This may result 
in reaching the bloodstream faster and being bioavailable quicker than tablet formulations 
(Hodges 2014). 
Theraflu Daytime Severe Cold & Cough powder for oral solution and Theraflu ExpressMax 
Daytime Severe Cold and Cough caplets are among the commercially available multi-symptom 
formulations available on the market. Theraflu Daytime Severe Cold & Cough powder for oral 
solution contains acetaminophen, phenylephrine and dextromethorphan and is available in 
sachets for reconstitution with hot water. 
Given that absorption of these active ingredients from the stomach is negligible but is rapid and 
significant from the duodenum, (Hengstmann  1982)  (Prescott L. 1996) rapid gastric emptying 
(GE) is a key approach to reducing the delay between drug ingestion and onset of symptom 
control. This clinical study is designed to characterize the gastrointestinal transit of Theraflu 
Daytime Severe Cold & Cough powder for oral solution and Theraflu ExpressMax Daytime 
Severe Cold and Cough caplets using gamma scintigraphy.
External gamma scintigraphy has been used extensively as a noninvasive technique for 
assessing the in vivo performance of drug delivery systems.  It provides information on 
deposition, dispersion and movement of radiolabeled dosage forms.  In this study, gamma 
scintigraphy will be utilized to monitor gastric emptying and intestinal transit of a single 
radioactive marker by [CONTACT_914819].
1.1 Mechanism of Action/Indication
Acetaminophen is an analgesic and antipyretic, its mechanism of action is believed to include 
inhibition of prostaglandin synthesis, primarily within the central nervous system. 
Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic receptors 
producing nasal decongestion. Finally, dextromethorphan has an antitussive action, it controls 
cough spasms by [CONTACT_914820] ([COMPANY_004] Global Data Sheet 2017).
1.2 Background and Rationale
This clinical study will be conducted to characterize the gastrointestinal transit of two multi-
symptoms formulations by [CONTACT_621394] a radiolabel marker: Theraflu Daytime Severe Cold & 
Cough powder for oral solution and Theraflu ExpressMax Daytime Severe Cold and Cough 
caplets. This study will be the first study to investigate the time of onset and completion of 
gastric emptying as well as small intestine transit time of Theraflu Daytime Severe Cold & 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 13 of 56Cough powder for oral solution and Theraflu ExpressMax Daytime Severe Cold and Cough 
caplets.
2 STUDY OBJECTIVES AND ENDPOINTS
Objective(s) Endpoint(s)
Gamma Scintigraphy Imaging
Characterize time to onset and time to 
completion of gastric emptying after 
administration of either Theraflu Daytime 
Severe Cold & Cough powder for oral 
solution to be reconstituted with 225 ml of 
hot water or Theraflu ExpressMax Daytime 
Severe Cold and Cough  caplets using gamma 
scintigraphic analysis. Mean time to onset of gastric emptying in 
healthy male volunteers who did not vomit 
shortly (within 60 minutes) after study drug 
administration, who have sufficient data to 
determine time to onset of gastric emptying 
and who had no major protocol deviations.  
Mean time to complete gastric emptying in 
healthy male volunteers who did not vomit 
shortly (within 60 minutes) after study drug 
administration, who have sufficient data to 
determine time to completion of gastric 
emptying and who had no major protocol 
deviations. 
Further characterize gastrointestinal 
emptying by [CONTACT_914821]: a) 
GE25%, GE50%, GE90% values, b) the 
amount remaining in the stomach at 15, 30, 
45, 60, 75, 90, 105, 120, 180, 240 min; c) 
sectional areas under the gastric emptying 
curve and total AUC; and d) gastric emptying 
t1/2 values.
e) Small intestinal transit times which are 
calculated by [CONTACT_914822] / colon 
region and subtracting the gastric emptying 
value.
Safety
To evaluate safety of Theraflu Daytime 
Severe Cold & Cough powder for oral Safety assessments consists of monitoring 
and recording adverse events (AEs) and 
laboratory test
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285831] POPULATION
This will be an open label, randomized, single dose, parallel group gamma scintigraphy. 
Approximately, forty-two healthy male volunteers will be screened to allow a total of 28 healthy 
male volunteers to be randomized (14 subjects per treatment arm) in order to have 24 evaluable 
subjects (12 subjects per treatment arm). 
Subjects will be randomized to receive either a single dose of Theraflu Daytime Severe Cold & 
Cough powder for oral solution (Treatment A) or a single dose of Theraflu ExpressMax 
Daytime Severe Cold and Cough caplets (Treatment B) under fasted conditions:): 
Treatment A – 12 healthy male volunteers will be administered 1 sachet of Theraflu 
Daytime Severe Cold & Cough radiolabeled powder for oral solution (acetaminophen 650 mg 
+ phenylephrine 10 mg + 20 mg dextromethorphan) reconstituted with 225 mL of hot water
Treatment B – 12 healthy male volunteers will take 2 radiolabeled caplets of Theraflu 
ExpressMax Daytime Severe Cold and Cough (2 caplets each containing acetaminophen 325 
mg + phenylephrine 5 mg + 10 mg dextromethorphan) with [ADDRESS_1285832] of screening visit (Visit 1), followed by a treatment visit (Visit 2). Visit 
2 includes two days: day -[ADDRESS_1285833] of relevant medical examinations. 
On visit 2 (day -1) of the study, study participants will be admitted to the unit at approximately 
[ADDRESS_1285834] (nothing to eat or 
drink except room temperature non-carbonated water) from [ADDRESS_1285835] is suitable for this protocol. Healthy 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285836] on the validity of the scintigraphy data. 
Vegetarians will be excluded from this study as there is evidence that the absorption of 
acetaminophen is impaired in this group of the population (Prescott, 1993). Female subjects 
will be similarly excluded; it has been observed that the menstrual cycle has been associated 
with changes in gastric emptying patterns (Wald, 1981). Subjects with allergies or intolerance 
to one or more ingredients of the standard meal will be excluded. Any subjects with a body 
mass index (BMI) higher than 30.5 kg/m2 will be excluded as shielding caused by [CONTACT_4210], muscle, 
other organs and soft tissue will attenuate counts.
4.[ADDRESS_1285837] eligibility should be reviewed and documented by [CONTACT_4653]’s study team before subjects are included in the study.
Subjects must meet all the following inclusion criteria to be eligible for enrollment into the 
study:
1. Evidence of a personally signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the study before any assessment is 
performed.
2. Healthy male subjects who, at the time of screening, are between the ages of 21 and 45 
years, inclusive.
3. Subjects who are willing and able to comply with scheduled visits, treatment plan, bio-
imaging procedure, laboratory tests and other study procedures.
4. Healthy subjects which is defined as in general good physical health, as judged by [CONTACT_395096] a detailed medical history, 
full physical examination, including blood pressure and pulse rate measurement, 12-lead 
ECG or clinical laboratory tests. 
5. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
4.2 Exclusion Criteria
Subjects with any of the following characteristics/conditions will not be included in the study:
1. Subjects who are investigational site staff members directly involved in the conduct of the 
study and their family members, site staff members otherwise supervised by [CONTACT_1275], or subjects who are [COMPANY_004] employees directly involved in the conduct of the 
study.
2. Participation in other studies involving investigational drug(s) within 30 days prior to 
study entry and/or during study participation.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285838] inappropriate for entry into this 
study.
4. Known or suspected intolerance or hypersensitivity or contraindication to the study 
materials (or closely related compounds) or any of their stated ingredients. 
5. Subject with known allergy or intolerance to any of the contents of the standard meals.
6. Subject is vegetarian.
7. Unwilling or unable to comply with the Lifestyle guidelines described in this protocol. 
8. Use of prescription or non-prescription drugs and dietary supplements within [ADDRESS_1285839] during Screening or 
on Day -1 of the study. 
11. Any condition possibly affecting drug absorption (e.g., gastrectomy) 
12. A history of current or relevant previous non-self-limiting gastrointestinal disorders peptic 
ulcer disease and/or gastrointestinal bleeding. 
13. Currently suffering from disease known to impact gastric emptying, e.g. migraine, insulin-
dependent diabetes mellitus.
14. The subject has had radiation exposure from clinical trials, including from the present study, 
and from therapeutic or diagnostic exposure, but excluding background radiation, exceeding 
a target organ (colon) dose of 50 mSv (5 rems) from a single dose within the last 30 days or 
a cumulative dose of 150 mSv (15 rems) in the last [ADDRESS_1285840] been exposed to ionising radiation in excess of 10 mSv (whole body 
effective dose) above background over the previous 3 years period as a result of 
occupational exposure or previous participation in research studies.  Clinically justified 
(therapeutic or diagnostic) exposures are not included in this calculation.
16. Renal disease or impaired renal function at screening as indicated by [CONTACT_914823] (e.g. albuminuria).  Minor deviations of laboratory values from the normal 
range are permitted, if judged by [CONTACT_914824].
17. History or current evidence of ongoing hepatic disease or impaired hepatic function at 
screening. A candidate will be excluded if more than one of the following lab value 
deviations are found: 1) AST/SGOT (≥ 1.[ADDRESS_1285841]), ALT/SGPT (≥ 1.[ADDRESS_1285842]), 2) GGT (≥ 
1.[ADDRESS_1285843]), ALP (≥ 1.[ADDRESS_1285844]), 3) total bilirubin (≥ 1.2 mg/dL) Minor deviations of 
laboratory values from the normal range are permitted, if judged by [CONTACT_914825] & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285845] no clinical relevance. Positive results in any of the virology tests for HIV-Ab, HCV-
Ab, HBsAg and HBc-Ab (Total).
18. Diagnosis of long QT syndrome or QTc > [ADDRESS_1285846] or abdominal area.
22. History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces 
(150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) 
within 6 months of Screening.
23. Smokers defined as the use of tobacco products (including but not limited to: electronic-
cigarettes, nicotine gums, nicotine lozenges, etc…) during the [ADDRESS_1285847] has consumed (eat or drink) grapefruit or grapefruit-related citrus fruits (e.g., 
Seville oranges, pomelos, pawpaw, dragon fruit, kiwi fruit, mango, passion fruit, 
pomegranate, rambutan, star fruit or products that contain these fruits) [ADDRESS_1285848] selection 
criteria to take 1 sachet of Theraflu Daytime Severe Cold & Cough powder for oral solution or 
2 caplets of Theraflu ExpressMax Daytime Severe Cold and Cough. Randomization schedule 
will be generated by [CONTACT_914826] (IHC).
4.4 Lifestyle Guidelines
4.4.1 Meals and Dietary Restrictions
Subjects must abstain from all food and drink (except water) at least [ADDRESS_1285849] 
administration. 
Water may be consumed without restriction beginning 4 hours after dosing.  
Non-caffeinated drinks (except grapefruit or grapefruit-related citrus fruit juices – see 
below) may be consumed with meals.
Lunch will be provided approximately 4 hours after dosing.
Dinner will be provided approximately 10 hours after dosing after the safety 
laboratory tests are performed.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 18 of 56Subjects will not be allowed to eat or drink grapefruit or grapefruit-related citrus fruits 
(e.g., Seville oranges, pomelos, pawpaw, dragon fruit, kiwi fruit, mango, passion fruit, 
pomegranate, rambutan, star fruit or products that contain these fruits) from [ADDRESS_1285850] until collection of the final 
scintigraphic image. 
While confined, the daily caloric intake per subject should not exceed approximately 
3200 kcal. 
4.4.2 Alcohol, Caffeine and Tobacco
Subjects will abstain from alcohol for 72 hours prior to admission to the clinical site 
and continue abstaining from alcohol until collection of the final scintigraphic image. 
Subjects will abstain from caffeine-containing products for 24 hours prior to 
admission to the clinical site until collection of the final scintigraphic image. 
Subjects are non-smokers for the last 6 months before the screening date and they will 
also abstain from the use of tobacco- or nicotine-containing products for 24 hours prior 
to admission to the clinical site and during confinement at the clinical site. 
4.4.3 Activity
Subjects will not be permitted to assume a fully recumbent position for 4 hours 
following dosing except during imaging and other required study procedures.
Subjects will abstain from strenuous exercise (e.g., heavy lifting, weight training, 
calisthenics, aerobics) for at least [ADDRESS_1285851] of contraception methods (see below) and instruct the subject in its consistent and correct 
use during the informed consent discussion.  Subjects need to affirm that they meet the criteria 
for the correct use of at least [ADDRESS_1285852]’s chart.  In addition, the investigator or his or her designee will 
instruct the subject to call immediately if the selected contraception method is discontinued or 
if pregnancy is known or suspected in the subject’s partner. 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285853] or female partner of childbearing potential to use of one of the highly effective 
methods of contraception are those that, alone or in combination, result in a failure rate of less 
than 1% per year when used consistently and correctly (i.e., perfect use) and include the 
following:
1. Established use of oral, inserted, injected, transdermal, or implanted hormonal methods of 
contraception is allowed provided the subject plans to remain on the same treatment 
throughout the entire study and has been using that hormonal contraceptive for an 
adequate period of time to ensure effectiveness as deemed appropriate by [CONTACT_093].
2. Correctly placed copper-containing intrauterine device (IUD). 
3. Male condom used WITH a spermicide (i.e., foam, gel, film, cream, or suppository). 
4. Male sterilization with documented absence of sperm in the post-vasectomy ejaculate.
5. Bilateral tubal ligation / bilateral salpi[INVESTIGATOR_74029] 
(provided that occlusion has been confirmed in accordance with the device’s label). 
Female partners of non-childbearing potential must meet at least one of the following criteria 
(medical documentation must be provided):
a. Achieved postmenopausal status, defined as follows: cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or physiological 
cause; status may be confirmed by [CONTACT_7661] a serum follicle-stimulating hormone 
(FSH) level confirming the post-menopausal state;  
b. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
c. Have medically confirmed ovarian failure.
All other female partners (including females with tubal ligations) will be considered to be of 
childbearing potential.
Male subjects should not donate sperm for the duration of the study and for [ADDRESS_1285854] 
dose. 
4.5 Screen Failures
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized. In order to ensure transparent reporting of screen failure subjects, 
a minimal set of screen failure information will include demography, screen failure details (e.g., 
withdrawal of consent), eligibility criteria, and any serious adverse events (SAEs). 
Individuals who do not meet the criteria for participation in this study (screen failure) may not 
be re-screened.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 20 of 564.6 Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study is documented in the study contact [CONTACT_914827], which should be filed in the Investigator Site File.
The contact [CONTACT_914828]; however, it should be used only in the event that the established 
communication pathways between the investigational site and the study team are not 
available.  It is therefore intended to augment, but not replace, the established communication 
pathways between the investigational site and the study team for advice on medical questions 
or problems that may arise during the study.  The contact [CONTACT_914829], and if some subject calls that number, he or she will be directed back to the 
investigational site.
To facilitate access to appropriately qualified medical personnel on study-related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137].  The contact [CONTACT_4662], at 
a minimum, protocol identifiers, subject study numbers, contact [CONTACT_914830], and contact [CONTACT_914831] a medical question or problem identified from the subject’s 
healthcare professional other than the investigator.  
5 STUDY TREATMENTS
The healthy male individuals will be randomized to take either treatment A:  1 sachet of 
Theraflu Daytime Severe Cold & Cough powder (Berry flavor) - (acetaminophen 650mg + 
Dextromethorphan 20mg + Phenylephrine 10mg) or treatment B: 2 caplets of Theraflu 
ExpressMax Daytime Severe Cold and Cough. (each caplet contains: acetaminophen 325 mg + 
Dextromethorphan 10mg + Phenylephrine 5mg). Both products will be commercially sourced 
from local market.
For treatment A:  Individual Theraflu doses are prepared by [CONTACT_914832] a glass bottle (with cap) and 225 mL of hot, but not boiling water (approximately 90-95°C), 
will be added to the container and mixed to dissolve the contents of the sachet. The dissolved 
Theraflu solution will be allowed to cool to approximately 40 – 50°C. After cooling, a small 
volume (1 to 10 microliters) of 99mTc-DTPA will be added to the drug solution in the preceding 
steps to achieve a maximum of 108 µCi (4 MBq) per individual dose at the time of dosing. The 
container will be capped and maintained at a temperature between 35-45°C until administration. 
For Treatment B: Individual caplet doses are prepared by [CONTACT_914833] a hole of approximately 1 
mm diameter and at a depth of approximately one-half of its thickness (~2-2.5 mm deep) into 
individual caplets.  99mTc-DTPA  (dissolved in normal saline) will be added into the hole of each 
caplet as a low volume liquid (0.5-2.0 microliters) to achieve a maximum of 54 µCi (2 MBq) 
per individual caplet at the time of dosing (two caplets = 108 µCi (4 MBq) dose per assessment 
visit). The applied liquid will be allowed to air dry and the hole is then filled with the equivalent 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 21 of 56powder blend from a crushed caplet such that the drug content will remain constant and the 
same for all caplets. The small surface area of the caplet that was altered may be sealed with an 
appropriate material if determined to be necessary. Radiolabeled caplets will be packaged as 
unit doses (2 caplets per container) and maintained at room temperature until administration.
A document describing the radiolabeling procedure of treatment A and B is detailed in 
Appendix 13.2 
For the purposes of this study, and per International Conference on Harmonization (ICH) 
guidelines, investigational product is defined as a pharmaceutical form of an active ingredient 
being tested or used as a reference in a clinical trial, including a product with a marketing 
authorization when used or assembled (formulated or packaged) in a way different from the 
approved form, or when used for an unapproved indication, or when used to gain further 
information about an approved use (ICH E6 R2 1.33).
5.1 Blinding and Allocation to Treatment/Randomization
Treatments will be provided in an open-label manner.  The investigator’s knowledge of the 
treatment should not influence the decision to enroll a particular subject nor affect the order in 
which subjects are enrolled nor influence the scintigraphy outcomes. Subjects knowing the 
product they are taking will also not affect the scintigraphy outcomes.
[COMPANY_004] CH will provide a randomization schedule to the investigator and, in accordance with the 
randomization numbers, the subject will receive the study treatment regimen assigned to the 
corresponding randomization number.
5.[ADDRESS_1285855] Compliance
Study treatment will be administered under the supervision of investigator site personnel. The 
emptiness of the mouth/tongue and containers will be checked after drug administration. A 
record of the administration of study formulations will be kept using the Dosing Accountability 
Log and the Case Report Form (CRF), any comments on the performance of this procedure 
should be recorded on the CRF. Any violation of compliance will require evaluation by [CONTACT_914834].  
5.[ADDRESS_1285856] Supplies
5.4.1 Dosage Form and Packaging
Treatment A, Theraflu Daytime Severe Cold & Cough sachets (acetaminophen 650 mg + 
phenylephrine 10 mg + 20 mg dextromethorphan sachet) and treatment B, Theraflu ExpressMax 
Daytime Severe Cold and Cough caplets (each containing acetaminophen 325 mg + 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 22 of 56phenylephrine 5 mg + 10 mg dextromethorphan) used in this study will be sourced 
commercially and supplied by [CONTACT_914835] (GCS). 
Treatment A, Theraflu Daytime Severe Cold & Cough powder for oral solution will be supplied 
to the study site in the commercial secondary package containing 6 individual sachets. The 
commercial secondary package will be labeled specifically for this study. 
Treatment B, Theraflu ExpressMax Daytime Severe Cold and Cough caplets will be supplied 
to the study site in the commercial secondary package containing 20 caplets, 2-10 count Blister 
cards. The commercial secondary package will be labeled specifically for this study.
The commercial secondary package labels will include, but not limited to the following 
information: the study number, Treatment or Product name, Batch number, storage conditions, 
expi[INVESTIGATOR_5695], the appropriate regulatory precautionary information, study site name [CONTACT_914846]. 
The manufacturers package information on product drug facts, warnings, directions, expi[INVESTIGATOR_4061], lot 
and storage conditions will not be defaced by [CONTACT_914836]. 
The study labels will be in accordance with all applicable regulatory requirements. Labeling 
will be carried out according to cGMP guidelines. Specific study label text for bulk supplies 
will be reviewed and approved internally by [CONTACT_914837] R&D Quality.
Bulk Packaging and labeling of the study products will be the responsibility of the Clinical 
Supply Department, [COMPANY_004]CH, Lincoln, NE, [LOCATION_003].
Care should be taken with the supplied products and their labels so that they are maintained in 
good condition.  It is important that all labels remain intact and legible for the duration of the 
study. The study labels are not to be removed or defaced.
Radiolabeling or individual dose labeling of the study treatments used in this study will be the 
responsibility of Scintipharma.
5.4.2 Preparation and Dispensing 
Radiolabeled Theraflu Daytime Severe Cold & Cough powder for oral solution and Theraflu 
ExpressMax Daytime Severe Cold and Cough caplets will be prepared, labeled and dispensed 
by [CONTACT_914838].
5.[ADDRESS_1285857] at 
approximately 8 am (plus or minus 2 hours).  Site personnel will administer investigational 
product as follows:
Treatment A: Hot radiolabeled Theraflu solution (225 mL) that will be prepared as described 
in section 5, will be allowed to cool sufficiently to be drinkable at a temperature between 35 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 23 of 56and 45°C at time of dosing and then subjects will be instructed to consume the hot drink entirely 
within 30 seconds.
Treatment B: 2 radiolabeled caplets will be swallowed with 225 mL of non-carbonated room 
temperature water. All the water (225 ml) should be consumed within [ADDRESS_1285858] whole, and will not manipulate or chew the 
medication prior to swallowing.
In order to standardize the conditions for scintigraphic imaging, all subjects will be required to 
refrain from lying down (except when required for imaging) and will not be allowed to eat or 
drink beverages (including water) for the first 4 hours after dosing. 
5.5.1 Medication Errors
Medication errors may result, in this study, from the administration or consumption of: 
the wrong product,
by [CONTACT_1148], 
at the wrong time, 
or at the wrong dosage strength (other examples of concern may be added based on 
the investigational product administration, such as inadvertent exposure).  
Such medication errors occurring to a study participant are to be captured in the CRF.  In the 
event of medication dosing error, the sponsor should be notified immediately.
Medication errors are reportable irrespective of the presence of an associated AE/SAE, 
including:
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that 
do or do not involve the participating subject.
Whether or not a medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_093], 
the medication error and, if applicable, any associated adverse event(s) is captured on AE CRF 
page.
5.[ADDRESS_1285859], will ensure that all 
investigational products Theraflu Daytime Severe Cold & Cough powder for oral solution and 
Theraflu ExpressMax Daytime Severe Cold and Cough caplets are stored in a secured area with 
controlled access under required storage conditions and in accordance with applicable 
regulatory requirements and product label.  
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room-temperature products).  This should be 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285860] receipt throughout the study.  Even for 
continuous monitoring systems, a log or site procedure that ensures active daily evaluation for 
excursions should be available.  The operation of the temperature-monitoring device and 
storage unit (for example, refrigerator), as applicable, should be regularly inspected to ensure it 
is maintained in working order. 
Any excursions from the product-label storage conditions should be reported upon discovery.  
The site should actively pursue options for returning the product to the storage conditions as 
described in the labeling, as soon as possible.  Deviations from the storage requirements, 
including any actions taken, must be documented and reported to the Sponsor.  
Once an excursion is identified, the investigational product must be quarantined and not used 
until the Sponsor provides documentation of permission to use the investigational product.  It 
will not be considered a protocol deviation if the sponsor approves the use of the investigational 
product after the temperature excursion.  Use of the investigational product prior to sponsor 
approval will be considered a protocol deviation.  Specific details regarding information the site 
should report for each excursion will be provided to the site. 
5.[ADDRESS_1285861] supplies.  All study drugs will be accounted for 
using a drug accountability form/record. 
The inventory must be available for inspection by [CONTACT_374791]. 
Monitoring of treatments accountability will be performed by [CONTACT_395105].
5.7.[ADDRESS_1285862] or certificate of 
destruction. At the conclusion of the study, the Principal Investigator [INVESTIGATOR_1075], 
and a representative of [COMPANY_004] CH will inventory all used and unused investigational study 
treatment.  
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 25 of 565.8 Concomitant Treatment(s)
Subjects will abstain from all concomitant treatments, except for those used for the treatment 
of AEs.
All concomitant treatments taken during the study must be recorded with indication, unit dose, 
daily dose, and start and stop dates of administration.  All subjects will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within [ADDRESS_1285863] selection criteria for the study.  
The following procedures will be completed:
Obtain written informed consent and record in the CRF.
Review Inclusion and Exclusion criteria and record in the CRF.
Collect demography, including year of birth and record in the CRF.
Collect height and weight. The results for each measurement will be recorded in the 
CRF.
Obtain medical history as related to the inclusion/exclusion criteria, including any 
relevant medical or surgical history, allergies or drug sensitivity, history of illegal 
drug, tobacco and alcohol use. Significant findings that are present from Informed 
Consent must be included in the CRF.
Obtain complete medication history of all prescription or nonprescription drugs, and 
dietary and herbal supplements taken within [ADDRESS_1285864] in the CRF.
Obtain supi[INVESTIGATOR_9204] (BP), pulse rate (PR), respi[INVESTIGATOR_697] (RR) and oral 
body temperature. The results for each measurement will be recorded in the CRF.
Conduct full physical examination. Any clinically relevant findings will be noted in 
the medical history CRF page and enrollment will be based upon investigator 
judgement.
Collect single 12-lead electrocardiogram (ECG). Results and any clinically significant 
abnormalities found will be recorded on the CRF.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 26 of 56Following at least a 4-hour fast, collect blood and urine specimens for the following, 
and record in the CRF:
Collect urine for drug screening test. Result will be recorded in the CRF.
Collect urine for cotinine test. Result will be recorded in the CRF.
Perform alcohol breath test. Result will be recorded in the CRF
Laboratory test (hematology, clinical chemistry, urinalysis, virology (HIV 
antibodies, HBsAg, anti-HBc (Total), anti-HCV)).
Assess symptoms by [CONTACT_914839] a non-leading question such as “How do you feel?” Any finding will be recorded on 
CRF
To prepare for study participation, subjects will be instructed on the use of the Lifestyle 
Guidelines  and Concomitant Treatment(s) sections of the protocol.
6.2 Study Period 1
For the study visits described below, when multiple procedures are scheduled at the same time 
point(s) relative to dosing, the following chronology of events should be adhered to, where 
possible.
6.2.1 Visit 2: Day -1 
Subjects will be admitted to the clinical site at approximately 7 pm prior to Day 1.  The 
following procedures will be completed following admission to the clinical site:
Review Inclusion and Exclusion criteria and record in the CRF.
Collect weight. The results for each measurement will be recorded in the CRF.
Obtain supi[INVESTIGATOR_9204] (BP), pulse rate (PR), respi[INVESTIGATOR_697] (RR) and oral body 
temperature. The results for each measurement will be recorded in the CRF.
Conduct full physical examination by [CONTACT_914840]. Any clinically relevant findings will be noted in the CRF, in the AE section.
Collect urine for drug screening test. Results will be recorded on the CRF.
Collect urine for cotinine test. Result will be recorded on the CRF.
Perform alcohol breath test. Result will be recorded on the CRF
Review changes in the subject’s medical history including medication history since 
Screening.. If the medical history condition worsens, the event will be recorded in the 
CRF, in the AE section.
Assess symptoms by [CONTACT_914839] a non-leading question such as “How do you feel?” Any finding will be recorded in 
CRF
Collect concomitant medications and record in the CRF.
Provide standardized dinner at around 9 pm.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285865] 10 hours prior to dosing on Day 1.
6.2.2 Visit 2: Day 1
Prior to randomization, the following procedures will be completed:
Conduct brief physical examination by [CONTACT_914840]. Any clinically relevant findings will be noted in the CRF, in the AE section.
Collect supi[INVESTIGATOR_395084]. The results for each measurement will 
be recorded in the CRF.
Assess symptoms by [CONTACT_914839] a non-leading question such as “How do you feel?” Any finding will be recorded in 
the CRF
Randomization
Administer the investigational product (see Study Treatments and Administration 
Sections). 
After dosing, the following procedures will be completed:
Collect images: A total of 30 image acquisitions will be recorded as follows: Anterior 
supi[INVESTIGATOR_914814] 60 second frame acquisitions and recorded at 0-15 
minutes (continuous imaging), 20, 25, 30, 35, 40, 45 min, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 
2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.5, 6, 7, 8, 9 and 10 hrs. A window of ± 2 
minutes will be allowed for each imaging period up to 1 hour (inclusive) and ± [ADDRESS_1285866] been acquired. 
Additional images may be acquired at the discretion of the investigator.
Record changes in concomitant medication in the CRF.
Assess symptoms by [CONTACT_914841] a non-leading question such as “How do you feel?” Any finding will be 
recorded in the CRF.
Provide standardized lunch meal [ADDRESS_1285867] dose.
After the last scintigraphic image is performed (~[ADDRESS_1285868] dose), collect vital signs 
(BP and PR), blood and urine for laboratory tests and record on the CRF. Conduct brief 
physical examination by [CONTACT_858115]. Any 
clinically relevant findings will be noted in the AE CRF page.
Provide standardized dinner meal after laboratory tests are performed.
Discharge the subject after all study procedures and fill in study completion page of 
CRF.
If a subject has any clinically significant, study-related abnormalities at the conclusion of a 
scheduled inpatient portion of the study, the [COMPANY_004] CH medical monitor (or designated 
representative) should be notified and depending on the abnormality, the subject may be asked 
to remain at the clinical site until such abnormalities are deemed not clinically significant, or it 
is safe for outpatient follow-up.  If the subject is unable or unwilling to remain at the clinical 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 28 of 56site and/or when outpatient follow-up is deemed appropriate, the [COMPANY_004] CH medical monitor (or 
designated representative) should be so notified, and the investigator should make every effort 
to arrange follow-up evaluations at appropriate intervals to document the course of the 
abnormalities.
6.[ADDRESS_1285869] to comply with the protocol-required schedule of study 
visits or procedures at a given study site.  
The following circumstances require discontinuation of study treatment and/or premature 
subject withdrawal:
Protocol violation that may impact the outcome of the subject’s safety
Withdrawal of informed consent
Vomiting shortly (within 60 minutes) after study drug administration
Subject lost to follow-up 
Death
If a subject is discontinued or prematurely withdraws from the study, reasons for 
discontinuation or withdrawal and associated date must be documented in the relevant section(s) 
of the CRF. 
If a subject does not return for a scheduled visit, every effort should be made to contact [CONTACT_1560].  The Investigator or site staff should attempt to contact [CONTACT_110280].  After two 
attempts, clinical site staff must send a registered letter.  If no response is received from the 
subject, the subject will be considered lost to follow up.  All attempts to contact [CONTACT_395107].  In any 
circumstance, every effort should be made to document subject outcome, if possible.  The 
investigator should inquire about the reason for withdrawal, request that the subject return for 
a final visit, if applicable, and follow-up with the subject regarding any unresolved AEs).
Lack of completion of all or any of the early termination procedures will not be viewed as 
protocol deviations so long as the subject’s safety was preserved.
If the subject withdraws from the study and also withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285870] be 
informed of these incidents in a timely manner.
7.1 Efficacy
Not applicable as there are no efficacy assessments.
7.2 Safety
The following safety assessments will be performed at times defined in the Study Procedures 
section of this protocol.  
7.2.1 Laboratory Tests 
Additional laboratory results may be reported on these samples as a result of the method of 
analysis or the type of analyzer used by [CONTACT_20019]; or as derived from calculated 
values.  These additional tests would not require additional collection of blood.  Unscheduled 
clinical labs may be obtained at any time during the study to assess any perceived safety 
concerns.
Blood and urine Human Biological Samples (HBS) will be collected for safety laboratory tests. 
The volume of individual blood samples collected will be up to 8.5 mL and the volume of 
individual urine samples collected will be up to 50 mL. All samples will be assigned unique 
tracking identifiers.
 
Samples (blood and urine) will be processed, labelled and couriered to the analytical laboratory 
the same day as collection. If a sample is collected and processed on a day when it cannot be 
couriered to the analytical laboratory, the sample will be processed and stored at conditions 
stated in the analytical laboratory sample manual.  Samples will be sent to and tested at Quest 
Diagnostics ([ADDRESS_1285871]., Wood Dale, IL [ZIP_CODE], [LOCATION_003]). Blood samples will be destroyed 
within 7 days of testing.
 
An aliquot of the urine sample will be taken for drug and cotinine testing at Scintipharma, Inc. 
([ADDRESS_1285872], Lexington, KY [ZIP_CODE], [LOCATION_003]).  Such aliquots will be disposed of in 
the sanitary sewer system within [ADDRESS_1285873] devices 
will be placed in medical waste and destroyed within 3 months of testing.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 30 of 56All samples will be tracked from collection to destruction on a HBS Tracking Log.
Table 7-1 Laboratory Tests
Hematology Chemistry Urinalysis Virology Other
Hemoglobin
Hematocrit 
RBC count 
MCV
MCH
MCHC
MPV
Platelet count 
WBC count
Total 
neutrophils 
(Abs)
Eosinophils 
(Abs)
Monocytes 
(Abs) 
Basophils 
(Abs) 
Lymphocytes 
(Abs)BUN/urea and 
Creatinine
Glucose (fasting) 
Calcium 
Magnesium 
Sodium 
Potassium 
Chloride
Total 
CO2(Bicarbonate)
 AST, ALT
Direct Bilirubin
Total Bilirubin
Alkaline 
phosphatase
Uric acid
Albumin
Total protein
GGT
PT/INRpH
Glucose (qual) 
Protein (qual) 
Blood (qual) 
Ketones 
Nitrites
Leukocyte 
esterase 
Urine Bilirubin
Specific gravity
MicroscopyaHIV-Ab 
HCV-Ab HBsAg 
and HBc-Ab 
(Total) Urine drug 
screenb
Breath alcohol
Urine cotinine
Definitions:  RBC= Red blood cell; MCV= Mean corpuscular volume; MCH= Mean corpusuclar 
hemoglobin; MCHC= Mean copusuclar hemoglobin concentration; MPV= Mean platelet volume; 
WBC= White blood cells; BUN=Blood urea nitrogen; HIV-Ab=Human Immunodeficiency Virus, HCV-
Ab=Antibodies Hepatitis C Virus, HBsAg=Surface antigen of Hepatitis B; b
AST= transaminase; ALT= alanine transaminase; PT/INR= prothrombin time/ international normalized 
ratio; GGT= Gamma-glutamyl transpeptidase.
a Only if urine dipstick is positive for blood, protein, nitrites or leukocyte esterase.
b Minimum requirement for drug testing includes: cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_232000], benzodiazepi[INVESTIGATOR_914815]; to be done at visit 1 and visit 2 (day-1)
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 31 of 567.2.2 Physical Examinations 
Physical examinations may be conducted by a physician, trained physician's assistant, or nurse 
practitioner as acceptable according to local regulation.  A full physical examination will 
include head, ears, eyes, nose, mouth, skin, and lung examinations, lymph nodes, 
gastrointestinal, musculoskeletal, cardiovascular and neurological systems.  
The brief physical examination will be focused on general appearance, the respi[INVESTIGATOR_395086], as well as towards subject reported symptoms.
Any untoward findings identified on physical exams will be captured as an adverse event, if 
those findings meet the definition of an AE.
7.2.3 Height and Weight 
Height in centimeters (cm) and body weight in kilograms (kg) to the nearest 0.[ADDRESS_1285874]’s arm supported at the level of the 
heart and recorded to the nearest mm Hg after approximately [ADDRESS_1285875].  The same arm 
(preferably the dominant arm) will be used throughout the study.  
The same properly sized and calibrated blood pressure cuff will be used to measure blood 
pressure each time. The use of an automated device for measuring BP and pulse rate is 
acceptable, although, when done manually, pulse rate will be measured in the brachial/radial 
artery for at least [ADDRESS_1285876] and before blood pressure measurement.
7.2.6 Temperature
Temperature will be measured orally. 
No eating, drinking or smoking is allowed for 15 minutes prior to the measurement.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285877] 12 lead ECG will be performed at screening visit (Visit 1). Interpretation of the 
tracing must be made by a qualified physician or designee and documented on the ECG section 
of the CRF. Each ECG tracing should be labeled with the study number, subject initials, subject 
number, date, and kept in the source documents at the study site. Results and clinically 
significant abnormalities should be reported in the CRF. Clinically significant abnormalities 
should also be recorded on the AE CRF page at the baseline visit. Clinically significant findings 
must be discussed with the [COMPANY_004] CPL prior to enrolling the subject in the study.
Subjects should be in a quiet environment and not speak during the resting period or 
measurement.  Generally, ECGs should not be collected within 3 hours after food or beverage 
consumption.
7.3 Gamma Scintigraphy Measurements and Evaluations
7.3.1 Scintigraphic Acquisition
External gamma scintigraphy has been used extensively as a noninvasive technique for 
assessing the in vivo performance of drug delivery systems. In this study, gamma scintigraphy 
will be utilized to monitor gastric emptying and intestinal transit of a single radioactive marker 
by [CONTACT_914819]. The radioactive isotope technetium-99m DTPA (99mTc, 
t½ 6 hr, γ = 140 keV) is added to drug formulation before ingestion. All radiolabeled dosage 
forms will be assayed using a standardized dose calibrator to determine radioactive content. In 
vitro validation tests will be completed to verify that radiolabeling procedures of the caplet do 
not alter dosage form pharmaceutical characteristics. The radiolabeling procedure of the caplet 
will be described in a separate document that will be available before study start, i.e. before 
FSFV.  Since the 99mTc-DTPA is not absorbed, gastrointestinal transit can be monitored using 
a gamma camera that captures images at frequent intervals after administration. Scintigraphic 
imaging will be performed with subjects in the supi[INVESTIGATOR_2547]. Except during imaging or while 
conducting other clinical procedures, subjects will remain in the upright position (seated, 
standing or walking) until at least four hours post dose. Subjects will undergo a series of 
consecutive anterior scintigraphic images, each of sixty seconds in duration on Day 1 of each 
period at 0-15 minutes (continuous) and at 20, 25, 30, 35, 40, 45 min, 1, 1.25, 1.5, 1.75, 2, 2.25, 
2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.5, 6, 7, 8, 9 and 10 hrs. A window of ± 2 
minutes will be allowed for each imaging period up to 1 hour (inclusive) and ± 3 minutes after 
1 hour.
The drug formulation will be radiolabeled with not more than 108 µCi (4 MBq) of 99mTc-DTPA. 
Prior to ingesting the radiolabeled formulation, two removable external markers (2-3 
microcuries of technetium-99m) will be placed on each subject to facilitate consistent 
positioning underneath the gamma camera. The first marker will be placed on the right side of 
the subject’s chest (approximately at the fifth intercostal rib) and a second marker will be placed 
on the hip bone (approximately the left anterior superior ileac spi[INVESTIGATOR_050]). The scintigraphy analysis 
software ScinWin (GammaForge, Louisville, KY) uses these markers to automatically align 
and register the images to the same relative position.  Variations in subject positioning or actual 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285878] movement are thereby [CONTACT_914842]. Scintigraphic 
imaging will begin immediately following ingestion of the radiolabeled drug formulation using 
a large field of view gamma camera (Siemens BasiCam) equipped with a low energy all-purpose 
parallel hole collimator.  The multi-channel analyzer will be set to 10-15% window and tuned 
to the 140 keV photopeak of 99mTc. 
Scintigraphic data will be recorded and stored electronically using ScinCam image acquisition 
software (GammaForge, Louisville, KY).
7.3.[ADDRESS_1285879] (ROI) will be 
drawn to include the stomach, proximal small intestine, distal small intestine and colon 
(SCINWIN, GammaForge, Louisville, KY). Each image will be corrected for radioactive decay 
and background radiation. The primary analysis will evaluate the gastric emptying time and 
first gastric emptying (or time to reach duodenum) and complete gastric emptying time. 
Parameters such as the following will be determined as necessary: time for half of the tracer to 
leave the stomach (T50% gastric emptying, GET 50%), small intestine transit time (SITT50 %), 
and time for half of the tracer to arrive at the colon (T50% colon arrival, ATC 50%). 
7.3.[ADDRESS_1285880] per dose (Treatment A or B) is 108 Ci (4.00 MBq) of 99mTc-DTPA on a 
single occasion. Treatment A will consist of a single dose of up to 108 Ci (4.00 MBq) of 99mTc-
DTPA and Treatment B will consist of two caplets containing up to 54 Ci (2.00 MBq) of 
99mTc-DTPA each for a total of up to 108 Ci (4.00 MBq) of 99mTc-DTPA.
The radiation dose from the administration of a 108 Ci total dose of 99mTc DTPA into the GI 
tract has been calculated (See Appendix 13.1). A total effective dose of up to 0.100 mSv (0.0100 
rems) will be administered.  The additional risk of developi[INVESTIGATOR_007] a fatal malignancy as a result of 
this exposure has been estimated as approximately 1 in 200,000 for an adult in normal health. 
(ICRP 2007).
The National Council on Radiation Protection and Measurements (NCRP) indicates that the 
effective dose from natural background radiation which everyone receives per year (excluding 
radon) is about 1 mSv (0.1 rems).  The average annual effective dose from radon alone is 
estimated as 2 mSv (0.2 rems) per year.  The NCRP indicates that larger exposures to more 
limited groups of persons are not especially hazardous, provided they do not occur often to the 
same groups. The NCRP has recommended that the maximum permissible annual effective dose 
be 5 mSv (0.5 rems) for individuals with infrequent exposure to radioactivity (NCRP 1993). 
For workers who are occupationally exposed to radioactivity, the NCRP recommends that the 
effective dose in any 1 year should not exceed 50 mSv (5 rems), which is approximately 
[ADDRESS_1285881] will receive in the present study. 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 34 of 56The primary target organ (upper colon wall) will receive a maximum dose of 0.458 mSv (0.0458 
rems) for the entire study, which is approximately 100 times lower than the recommended 
maximum amount of radiation exposure to a target organ achieved after a single dose (50 mSv 
or 5 rems) of a radiopharmaceutical, and lower than the annual recommended amount of 
radiation exposure to a target organ (150 mSv or 15 rems), as specified in [ADDRESS_1285882] been 
exposed to ionizing radiation exceeding an effective dose of 10 mSv (1 rem) above background 
over the previous 3 year period as a result of occupational exposure or previous participation in 
research studies, not including clinically justified (therapeutic or diagnostic) exposures, will be 
excluded. 
7.[ADDRESS_1285883] in this study is approximately 54 .5 mL.  The 
table below reflects approximate sample volumes needed for each measured endpoint.  The 
actual collection times of blood sampling may change, but the total blood volume collected will 
not increase.  Additional blood samples may be taken for safety assessments at the discretion 
of the investigator or [COMPANY_004] CH.
Table 7-2 Blood Volume
Sample Volume (mL) Sample Type
Screening Study PeriodTotal Volume (mL)
Safety Labs 33.[ADDRESS_1285884] or medical device.
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study treatment.
Events Meeting the AE Definition:  
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 35 of 56Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underlying disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae.
Events NOT meeting the AE definition: 
Any clinically significant abnormal laboratory findings (if applicable) or other abnormal 
safety assessments which are associated with the underlying disease, unless judged by 
[CONTACT_1173]’s condition. 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
Medical or surgical procedure (e.g., endoscopy, appendectomy) is not the AE. The 
condition that leads to the procedure is an AE (e.g., appendicitis).
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
8.1.2 Serious Adverse Event
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).
A SAE is any untoward medical occurrence at any dose that:
Results in death
Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe;
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 36 of 56Requires inpatient hospi[INVESTIGATOR_1081] 
In general, hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_1085], the event is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred, or was necessary, the AE should be considered 
serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not 
worsen from baseline is not considered an AE.
Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption
Results in congenital anomaly/birth defect
Other situations
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_165753]. These events 
should usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.
8.2 Reporting Period
8.2.1 Adverse Event
AEs (serious and nonserious) will be collected from the signing the informed consent and until 
[ADDRESS_1285885] a run-
in period or washout period, adverse events will be collected from the time the run-in or washout 
period begins. 
Medical occurrences that start after obtaining informed consent will be recorded on the AE 
section of the case report form (CRF) 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 37 of 568.2.2 Serious Adverse Event
SAEs assessed as related to study participation (e.g., investigational product, protocol 
mandated procedures, invasive tests, or change in existing therapy) or related to a [COMPANY_004] 
concomitant medication will be recorded from the time a subject provides informed consent, 
which is obtained prior to the subject’s participation in the study, i.e., prior to undergoing any 
study-related procedure and/or receiving investigational product and until [ADDRESS_1285886].
SAEs assessed as not related to study participation (e.g., investigational product, protocol 
mandated procedures, invasive tests, or change in existing therapy) or not related to a [COMPANY_004] 
concomitant medication will be recorded from the signing of informed consent and until [ADDRESS_1285887] will be questioned about AEs. 
Each AE is to be assessed to determine if it meets the criteria for SAEs.  If an SAE occurs, 
expedited reporting will follow local and international regulations, as appropriate.
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to the event.
The investigator or site staff will then record all relevant information regarding an AE/SAE in 
the CRF.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical records 
to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may be instances when copi[INVESTIGATOR_395088].  
In this instance, all subject identifiers, with the exception of the subject number, will be blinded 
on the copi[INVESTIGATOR_395089].
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information.  In such cases, the diagnosis will be documented as the 
AE/SAE and not the individual signs/symptoms. Clinical AEs will be described by [CONTACT_395108] (e.g., upper respi[INVESTIGATOR_1092], seasonal allergy, 
etc. instead of runny nose).
Medical conditions reported prior to the time period for reporting AEs/SAEs should be recorded 
as part of the subject’s medical history.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285888] manner at the study visits should also be recorded 
in the AE section of the CRF. Care will be taken not to introduce bias when detecting AE and/or 
SAE. Open-ended and non-leading verbal questioning of the participant is the preferred method 
to inquire about AE occurrence.
8.3.1 Adverse Event
All AEs will be reported on the AE page(s) of the CRF by [CONTACT_132018].  It should 
be noted that the form for collection of SAE information is not the same as the AE CRF.  Where 
the same data are collected, the forms must be completed in a consistent manner.  For example, 
the same AE term should be used on both forms.  AE should be reported using concise medical 
terminology on the CRF as well as on the form for collection of SAE information.
8.3.2 Serious Adverse Event
A paper copy of the SAE form provided in the investigator study master file should be 
completed as fully as possible. 
It is essential to enter the following information: 
Protocol and subject identifiers
Subject’s demography
Description of events, with diagnosis if available
Investigator opi[INVESTIGATOR_65348] 
Criterion for seriousness.
The following are desirable and are of particular relevance for investigator and [COMPANY_004] CH 
assessment of the SAE report:
Date of onset of AE 
Date AE stopped, if relevant
Study product start date
Study product end date if relevant
Action taken on study product
Outcome if known
The SAE form, completed as fully as possible, must be e-mailed to the [COMPANY_004] CH Clinical 
Operations Safety Reporting email box with the study number and subject number in the subject 
line of the email immediately and under no circumstance should this exceed 24 hours  after 
study site personnel learn of the event. The investigator will submit any updated SAE data to 
the sponsor, immediately and  under no circumstance should this exceed 24 hours of it being 
available. The [COMPANY_004] CH Study Manager should also be notified of the situation by [CONTACT_19385].
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: 2 2-J u n- 2 0 1 7 
Pa ge 3 9  of 5 6 E m ail Seri o us A d verse E ve nts t o: 
T he G S K C H St u d y Ma na ger or desi g nee will be res p o nsi ble f or f or war di n g t he S A E f or m t o 
t he Case Ma na ge me nt Gr o u p, Gl o bal Cli nical Safet y a n d P har mac o vi gila nce mail b o x 
( ). 
T he i nitial re p ort will be f oll o we d u p wit h m ore i nf or mati o n as rele va nt, or as re q ueste d b y t he 
G S K C H st u d y ma na ger. 
8. 3. 3 S p o n s or’ s R e p orti n g R e q uir e m e nt s t o R e g ul at or y A ut h oriti e s a n d 
Et hi c s C o m mitt e e s 
G S K has a le gal res p o nsi bilit y t o n otif y, as a p pr o priate, t he l ocal re g ulat or y a ut h orit y a n d ot her 
re g ulat or y a ut h orities a b o ut t he safet y of a pr o d uct u n der cli nical i n vesti gati o n.  Pr o m pt 
n otificati o n of S A Es b y t he i n vesti gat or t o G S K is esse ntial s o t hat le gal o bli gati o ns a n d et hical 
res p o nsi bilities t o war ds t he safet y of s u bjects are met. 
G S K will c o m pl y wit h c o u ntr y s pecific re g ulat or y re q uire me nts relati n g t o safet y re p orti n g t o 
t he re g ulat or y a ut h orit y, I R B/ E C a n d i n vesti gat ors. 
I n vesti gat or safet y re p orts m ust be pre pare d f or s us pecte d u ne x pecte d seri o us a d verse reacti o ns 
( S U S A R) acc or di n g t o l ocal re g ulat or y re q uire me nts a n d s p o ns or p olic y a n d f or war de d t o 
i n vesti gat ors as necessar y. 
A n i n vesti gat or w h o recei ves a n i n vesti gat or safet y re p ort descri bi n g a S A E or ot her s pecific 
safet y i nf or mati o n e. g., s u m mar y or listi n g of S A E) fr o m t he s p o ns or will re vie w a n d t he n file 
it al o n g wit h t he I n vesti gat or’s Br oc h ure a n d will n otif y t he I R B/I E C, if a p pr o priate acc or di n g 
t o l ocal re q uire me nts. 
8. [ADDRESS_1285889] u d y a n d will assi g n it t o o ne of t he f oll o wi n g cate g ories: 
Mil d:  A n e ve nt t hat is easil y t olerate d b y t he s u bject, ca usi n g mi ni mal disc o mf ort a n d 
n ot i nterferi n g wit h e ver y da y acti vities. 
M o derate:  A n e ve nt t hat is s ufficie ntl y disc o mf orti n g t o i nterfere wit h n or mal e ver y da y 
acti vities 
P P D 
Se vere:  A n e ve nt t hat pre ve nts n or mal e ver y da y acti vities. 
N ote: A n A E t hat is assesse d as se vere will n ot be c o nf use d wit h a n S A E. Se verit y is a cate g or y 
utilize d f or rati n g t he i nte nsit y of a n e ve nt; a n d b ot h A Es a n d S A Es ca n be assesse d as se vere. P P D 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 40 of 56For example, a headache may be severe (interferes significantly with the subject's usual function) 
but would not be classified as serious unless it met one of the criteria for SAEs, listed above. 
8.4.2 Causality Assessment
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. For each AE/SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessment of causality. The 
investigator’s assessment of causality must be provided for all AEs (serious and non-serious); 
the investigator must record the causal relationship in the CRF, as appropriate, and report such 
an assessment in accordance with the SAE reporting requirements if applicable.
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Generally, the facts (evidence) or arguments to suggest a causal relationship should be provided.
The investigator will use clinical judgment to determine the relationship and will also consult 
the Investigator Brochure (IB), Safety Statement and/or Product Information, for marketed 
products, in the determination of his/her assessment.  Alternative causes, such as underlying 
disease(s), concomitant therapy, other risk factors, and the temporal relationship of the event to 
the study product will be considered and investigated.
There may be situations when an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004].  However, it is very important that the 
investigator always make an assessment of causality for every event prior to the initial 
transmission of the SAE data to [COMPANY_004]. The investigator may change his/her opi[INVESTIGATOR_1095]-up information and send an SAE follow-up report with the updated 
causality assessment. 
8.[ADDRESS_1285890] administration does not need to be collected.
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: [ADDRESS_1285891] will be f oll o we d t o deter mi ne t he 
o utc o me of t he pre g na nc y. I nf or mati o n o n t he stat us of t he m ot her a n d i nfa nt / ne o nate 
(i ncl u di n g c o nc o mita nt me dicati o ns ta ke n b y t he m ot her d uri n g t he pre g na nc y) will be 
f or war de d t o G S K. Ge nerall y, f oll o w- u p will be n o l o n ger t ha n 6 t o 8 wee ks f oll o wi n g t he 
esti mate d deli ver y date. A n y ter mi nati o n of t he pre g na nc y will be re p orte d. 
W hile pre g na nc y itself is n ot c o nsi dere d t o be a n A E, a n y pre g na nc y c o m plicati o n or 
electi ve ter mi nati o n f or me dical reas o ns will be rec or de d as a n A E or S A E as defi ne d i n 
Secti o n 8. 1. 
A s p o nta ne o us a b orti o n is al wa ys c o nsi dere d t o be a n S A E a n d will be re p orte d as s uc h. A n 
S A E occ urri n g i n ass ociati o n wit h a pre g na nc y, br o u g ht t o t he i n vesti gat or’s atte nti o n after t he 
s u bject c o m plete d t he st u d y a n d c o nsi dere d b y t he i n vesti gat or as p ossi bl y relate d t o t he 
i n vesti gati o nal pr o d uct, m ust be pr o m ptl y f or war de d t o G S K. W hile t he i n vesti gat or is n ot 
o bli ge d t o acti vel y see k t his i nf or mati o n i n f or mer st u d y partici pa nts, he or s he ma y lear n of a n 
S A E t hr o u g h re p orti n g. 
8. [ADDRESS_1285892]’s c o n diti o n. 
All A Es/ S A Es will be f oll o we d u ntil res ol uti o n, u ntil t he c o n diti o n sta bilizes, u ntil t he e ve nt is 
ot her wise e x plai ne d, or u ntil t he s u bject is l ost t o f oll o w- u p.  
T he i n vesti gat or is o bli gate d t o perf or m or arra n ge f or t he c o n d uct of s u p ple me ntal 
meas ure me nts a n d/ or e val uati o ns as ma y be i n dicate d or as re q ueste d b y G S K t o el uci date as 
f ull y as p ossi ble t he nat ure a n d/ or ca usalit y of t he A E or S A E. T his ma y i ncl u de a d diti o nal 
la b orat or y tests or i n vesti gati o ns, hist o pat h ol o gical e xa mi nati o ns, or c o ns ultati o n wit h ot her 
healt h care pr ofessi o nals. 
Ne w or u p date d i nf or mati o n will be rec or de d i n t he ori gi nall y c o m plete d C R F. 
T he i n vesti gat or will s u b mit a n y u p date d S A E data t o G S K wit hi n [ADDRESS_1285893] u d y partici pati o n, t he i n vesti gat or will pr o m ptl y n otif y G S K b y e maili n g t he 
i nf or mati o n t o t he G S K C H Cli nical O perati o ns Safet y Re p orti n g e mail b o x ( 
). T he G S K C H St u d y Ma na ger or desi g nee will be res p o nsi ble f or 
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: 2 2-J u n- 2 0 1 7 
Pa ge 4 2  of 5 6 f or war di n g t he i nf or mati o n t o t he Case Ma na ge me nt Gr o u p, Gl o bal Cli nical Safet y a n d 
P har mac o vi gila nce gr o u p mail b o x at G S K ( ). 
T he i n vesti gat or will s u b mit a n y u p date d S A E data t o G S K wit hi n t he desi g nate d re p orti n g ti me 
fra mes. 
[ADDRESS_1285894] data will be e ntere d i nt o a n electr o nic C R F, usi n g a vali date d data s yste m. 
9. 1 S o ur c e D o c u m e nt s/ D at a 
T he s o urce d oc u me nts (e. g., h os pi[INVESTIGATOR_21036], cli nical a n d office c harts, la b orat or y n otes, 
me m ora n da, s u bjects’ diaries or e val uati o n c hec klists, p har mac y dis pe nsi n g rec or ds, rec or de d 
data fr o m a ut o mate d i nstr u me nts, micr ofic hes, p h ot o gra p hic ne gati ves, micr ofil m or ma g netic 
me dia, x-ra ys, s u bject files a n d rec or ds ke pt at t he p har mac y, at t he la b orat or y a n d at t he 
me dic o-tec h nical de part me nts i n v ol ve d i n t he cli nical st u d y) w hic h c o ntai n t he s o urce of data 
rec or de d i n t he C R F s h o ul d be s pecifie d i n Secti o n [ADDRESS_1285895] w h o has gi ve n i nf or me d c o nse nt/asse nt a n d has bee n scree ne d, C R F m ust be 
c o m plete d a n d si g ne d b y t he Pri nci pal I n vesti gat or ( or a ut h orize d desi g nee) t o certif y t hat t he 
data are c o m plete a n d c orrect.  
Ma na ge me nt of cli nical data will be perf or me d i n acc or da nce wit h a p plica ble Ve n d or a n d G S K 
C H sta n dar ds, a n d data clea ni n g pr oce d ures t o e ns ure t he i nte grit y of t he data e. g. re m o vi n g 
err ors a n d i nc o nsiste ncies i n t he data. 
I n or der t o pr otect t he pri vac y of s u bjects, n o Pers o nall y I de ntifia ble I nf or mati o n ( PII) 
(i ncl u di n g t he s u bject's na me or i nitials or f ull birt h date) is t o be rec or de d i n t he C R F or as part 
of t he q uer y te xt. 
All C R F pa ges s h o ul d be c o m plete d d uri n g a s u bject assess me nt w he n t he C R F has bee n 
desi g nate d as t he s o urce.  Data t hat is s o urce d else w here s h o ul d be e ntere d i nt o t he C R F i n a n 
a gree d u p o n ti mefra me bet wee n t he I n vesti gat or a n d S p o ns or.  
G S K C H will o btai n a n d retai n all C R Fs a n d ass ociate d st u d y data at t he c o m pleti o n of t he 
st u d y. 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 43 of 569.3 Data Handling
Documentation of all data management activities should allow step-by-step retrospective 
assessment of data quality and study performance. 
Any changes or corrections to data will be performed in the Electronic Data Capture (EDC) 
System, and it will include rationale for changes. The EDC system has an audit trail, which will 
provide a complete record of the changes and corrections endorsed by [CONTACT_737].
AEs will be coded using MedDRA (Medical Dictionary for Regulatory Activities) and 
concomitant medications terms (if applicable) using an internal validated medication dictionary, 
[COMPANY_004] Drug.  
9.3.1 Queries
Programmed edit checks will be generated automatically, as the data is being entered into the 
system. Data Management will also run reports and listings on the CRF data, in addition to the 
queries already programmed and generated by [CONTACT_1190], to raise manual queries as needed 
for site clarification or correction. The Clinical Dictionary Development and Management 
Group will raise queries as needed on safety data to code the terms (AEs and Drugs) 
appropriately. 
The study monitor at the study site will review the CRFs in accordance with the monitoring 
plan, and any queries will be generated in the EDC System to the Investigator or designee, 
enabling the errors to be addressed in parallel with Data Management review. The study monitor 
can also run reports and listings on the CRFs, to raise manual queries as needed for site 
clarification or correction.
9.[ADDRESS_1285896] and time point referenced in the CRF and/or 
protocol. 
An agreed upon quality control process is performed against the transcribed data to the source 
to ensure the accuracy of the transcription. The transcribed data is transmitted in an agreed upon 
format to [COMPANY_004] CH. 
Reconciliation will be performed between the transcribed data and the clinical database to 
ensure subject and time point referenced in the Clinical Database match before Clinical 
Database Freeze (locking of the database) can occur.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285897] 24 subjects evaluable ([ADDRESS_1285898] per arm). This is a sufficient 
number to provide descriptive statistics. 
10.2 Statistical Methods and Analytical Plan
Additional details of the proposed statistical analysis will be documented in the statistical 
analysis plan (SAP), which will be written following finalization of the protocol and prior to 
study analysis (as appropriate).
10.2.1 Demographic and Baseline Characteristics
Baseline data (i.e. the last available value prior to the start of the treatment phase), relevant 
screening data and demographic characteristics will be summarized for the safety population.
10.2.2 Scintigraphy Analysis
The scintigraphy variables are:
time to onset of gastric emptying for treatment arm A and B.
 time to completion of gastric emptying for treatment arm A and B.
GE25%, GE50%, GE90% values for each treatment A and B, 
 the amount remaining in the stomach at 15, 30, 45, 60, 75, 90, 105, 120, 180, 240 min 
for each Treatment arm A and B 
sectional areas under the gastric emptying curve and total AUC; and gastric emptying 
t1/2 values. 
small intestinal transit times for each treatment arm A and B.
The scintigraphy variables of scintigraphic analysis will be summarized by [CONTACT_529772] (mean, minimum, median, maximum and standard deviation, CVs and 95% 
CI for the Means). There are no formal hypotheses being tested in this study.
[IP_ADDRESS] Criteria for assessing Scintigraphy
Use the scintigraphic images to measure the gastric emptying time to onset and completion as 
for treatment arms A and B. 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 45 of 5610.2.3 Safety Analysis
Safety variables will be summarized for the safety population.
Adverse Event:
Treatment Emergent AEs, i.e. AEs that are emergent or that worsen after the administration of 
treatment arm A or B, will be summarized by [CONTACT_1601], for each treatment, the number and 
percentage of subjects having any AE, any AE in each MedDRA System Organ Class (SOC) 
and having each individual AE. The subset of AEs suspected of a relationship to study drug will 
be presented similarly. All treatment-emergent AEs will also be tabulated by [CONTACT_926]. Any other 
information collected (e.g. action taken, duration, outcome) will be listed. Each AE will be 
attributed to the treatment taken most recently before the onset of the AE.
Physical examination
Physical Examination data will be listed with abnormal values flagged.
Laboratory tests:
Laboratory data will be listed with abnormal values flagged.
[IP_ADDRESS] Criteria for assessing safety
Laboratory tests and monitoring of AEs as well as brief physical examination outcomes will be 
used to assess the safety and tolerability of the study products
10.2.4 Definition of Analysis Populations
Scintigraphy analysis population will be conducted on all subjects who received the 
radiolabeled treatments arm A or B and who did not vomit shortly (within 60 minutes) after 
study drug administration, who have sufficient data to determine time to onset and completion 
of gastric emptying and who had no major protocol deviations.
The Safety population will include all subjects who receive a radiolabeled hot drink 
independently if they are included or not in the scintigraphy analysis.
10.2.5 Exclusion of Data from Analysis 
Exclusion of any data from the analyses will be determined during a Data Review Meeting prior 
to database lock. Any reasons for exclusion from an analysis population will be listed, if 
applicable.
10.2.6 Handling of Dropouts and Missing Data 
Subjects who drop out will not be replaced, i.e. their randomization number will not be re-used.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 46 of 5610.2.7 Interim Analysis 
No interim analysis is planned for this study
11 STUDY GOVERNANCE CONSIDERATIONS
11.1 Quality Control 
In accordance with applicable regulations including GCP, and [COMPANY_004] procedures, [COMPANY_004] or 
designee (i.e. third party vendor) monitors will contact [CONTACT_395117], study requirements, and their responsibilities to satisfy 
regulatory, ethical, and [COMPANY_004] requirements.
When reviewing data collection procedures, the discussion will include identification, 
agreement and documentation of data items for which the CRF will serve as the source 
document.
[COMPANY_004] or designee will monitor the study and site activity to verify that the:
Data are authentic, accurate, and complete.
Safety and rights of subjects are being protected.
Study is conducted in accordance with the currently approved protocol and any other 
study agreements, GCP, and all applicable regulatory requirements.
The extent and nature of monitoring will be described in a written monitoring plan on file at 
[COMPANY_004] CH. The investigator (or designee) agrees to allow the monitor direct access to all relevant 
documents and agrees to co-operate with the monitor to ensure that any problems detected in 
the course of these monitoring visits are resolved.
11.[ADDRESS_1285899] 
a quality assurance assessment and/or audit of the site records, and the regulatory agencies may 
conduct a regulatory inspection at any time during or after completion of the study. 
In the event of an assessment, audit or inspection, the investigator (and institution) must agree 
to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and 
to allocate their time and the time of their staff to discuss the conduct of the study, any 
findings/relevant issues and to implement any corrective and/or preventative actions to address 
any findings/issues identified.
The investigator(s) will notify [COMPANY_004] CH or its agents immediately of any regulatory inspection 
notification in relation to the study. Furthermore, the investigator will cooperate with [COMPANY_004] CH 
or its agents to prepare the study site for the inspection and will allow [COMPANY_004] CH or its agent, 
whenever feasible, to be present during the inspection. The investigator will promptly apply 
copi[INVESTIGATOR_65351]. Before response submission to the 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285900]/ Ethics Committee 
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent documents, investigator brochure/safety statement 
(including any updates) and other relevant documents, e.g., recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator file.  Copi[INVESTIGATOR_1099]/EC approvals should be forwarded to [COMPANY_004] CH prior to the 
initiation of the study, and also when subsequent amendments to the protocol are made.
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that 
event, the investigator must notify the IRB/EC and [COMPANY_004] CH in writing immediately after the 
implementation.
11.3.[ADDRESS_1285901] of the Study
The study will be conducted in accordance with legal and regulatory requirements, as well as 
the general principles set forth in the International Ethical Guidelines for Biomedical Research 
Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), 
guidelines for GCP (ICH 1996 and revision 2), and the Declaration of Helsinki (World Medical 
Association 2013). 
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws.
11.3.[ADDRESS_1285902]’s numerical code to his or her actual identity.  In case of data transfer, [COMPANY_004] CH 
will maintain high standards of confidentiality and protection of subjects’ personal data 
consistent with applicable privacy laws.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285903] be reviewed 
and approved by [CONTACT_456], approved by [CONTACT_1201]/EC before use, and available for inspection.
The investigator must ensure that each study subject is fully informed about the nature and 
objectives of the study and possible risks associated with participation. 
The investigator, or a person designated by [CONTACT_093], will obtain written informed 
consent from each subject before any study-specific activity is performed.  The investigator will 
retain the original of each subject's signed informed consent document.
11.3.[ADDRESS_1285904] Recruitment 
Advertisements approved by [CONTACT_1202]/ECs and investigator databases may be used as recruitment 
procedures.  Use of ethics committee approved, generic, prescreening questionnaire to assess 
basic subject characteristics to determine general eligibility for this study is allowed.  This 
generic questionnaire may be used by [CONTACT_1203] a phone script and/or to review internal databases 
to identify subjects.  
[COMPANY_004] CH will have an opportunity to review and approve the content of any study recruitment 
materials directed to potential study subjects before such materials are used. 
11.3.[ADDRESS_1285905] research studies. 
In the event of any prohibition or restriction imposed (i.e., clinical hold) by [CONTACT_1204], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_004] CH should be informed immediately. 
In addition, the investigator will inform [COMPANY_004] CH immediately of any urgent safety measures 
taken by [CONTACT_1205], and of any 
serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
11.4 Posting of Information on Publicly Available Clinical Trial 
Registers
Study information from this protocol will be posted on publicly available clinical trial registers 
before enrollment of subjects begins in accordance with applicable [COMPANY_004] processes.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285906] maintain all site study records (except for 
those required by [CONTACT_1206]), in a safe and secure location.  
The records (study/ site master file) must be maintained to allow easy and timely retrieval, when 
needed (e.g., for a [COMPANY_004] audit or regulatory inspection) and must be available for review in 
conjunction with assessment of the facility, supporting systems, and relevant site staff.
Where permitted by [CONTACT_1207]/regulations or institutional policy, some or all of these records 
can be maintained in a format other than hard copy (e.g., microfiche, scanned, electronic); 
however, caution needs to be exercised before such action is taken. 
The investigator must ensure that all reproductions are legible and are a true and accurate copy 
of the original and meet accessibility and retrieval standards, including re-generating a hard 
copy, if required.  Furthermore, the investigator must ensure there is an acceptable back-up of 
these reproductions and that an acceptable quality control process exists for making these 
reproductions.
The investigator must assure that the subject’s anonymity will be maintained.  On CRFs or other 
documents submitted to [COMPANY_004] CH, subjects should not be identified by [CONTACT_1208], 
but by [CONTACT_1209]. The investigator should keep a separate log of subjects’ codes, 
names and addresses.  Documents not for submission to [COMPANY_004] CH, e.g. subjects’ written consent 
forms, should be maintained by [CONTACT_1210].
Records and documents, including signed ICF, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] 25 years from the issue of the final Clinical Study Report (CSR)/ 
equivalent summary unless local regulations or institutional policies require a longer retention 
period. The minimum retention time will meet the strictest standard applicable to that site for 
the study, as dictated by [CONTACT_65406], [COMPANY_004] 
standards/procedures, and/or institutional requirements.  
No study document should be destroyed without a prior written agreement between [COMPANY_004] CH 
and the investigator. The investigator must notify [COMPANY_004] of any changes in the archival 
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: [ADDRESS_1285907] u d y ma y occ ur beca use of a re g ulat or y a ut h orit y decisi o n, 
c ha n ge i n o pi [INVESTIGATOR_9384] o n of t he I R B/ E C, or i n vesti gati o nal pr o d uct safet y pr o ble ms, or at t he discreti o n 
of G S K C H.  
If a st u d y is pre mat urel y ter mi nate d, G S K C H will pr o m ptl y n otif y t he i n vesti gat or.  After 
n otificati o n, t he i n vesti gat or m ust pr o m ptl y c o ntact all partici pati n g s u bjects a n d s h o ul d ass ure 
a p pr o priate t hera p y/ f oll o w- u p f or t he s u bjects.  As directe d b y G S K C H, all st u d y materials 
m ust be c ollecte d a n d all C R Fs c o m plete d t o t he greatest e xte nt p ossi ble. W here re q uire d b y 
t he a p plica ble re g ulat or y re q uire me nts, G S K C H s h o ul d i nf or m t he re g ulat or y a ut h orit y(ies) 
a n d t he i n vesti gat or s h o ul d pr o m ptl y i nf or m t he I R B/ E C a n d pr o vi de t he I R B/ E C a detaile d 
writte n e x pla nati o n of t he ter mi nati o n or s us pe nsi o n. 
If t he I R B/ E C ter mi nates or s us pe n ds its a p pr o val/fa v ora ble o pi [INVESTIGATOR_9384] o n of a trial, t he i n vesti gat or 
s h o ul d pr o m ptl y n otif y t he G S K C H a n d pr o vi de G S K C H wit h a detaile d writte n e x pla nati o n 
of t he ter mi nati o n or s us pe nsi o n. U p o n c o m pleti o n or pre mat ure disc o nti n uati o n of t he st u d y, 
t he G S K C H m o nit or will c o n d uct site cl os ure acti vities wit h t he i n vesti gat or or site staff, as 
a p pr o priate, i n acc or da nce wit h a p plica ble re g ulati o ns i ncl u di n g G C P, a n d G S K C H Sta n dar d 
O perati n g Pr oce d ures 
[ADDRESS_1285908] u d y E n d/ E n d of St u d y 
St u d y E n d ( S E) date is defi ne d as t he date of t he last s u bject visit of t he last s u bject t o c o m plete 
t he st u d y ( L S L V).  
1 2  R E F E R E N C E S 
[ G walt ne y Jr J M, P hilli ps C D, Miller R D et al, ( 1 9 9 4)] C o m p ute d t o m o gra p hic st u d y of t he 
c o m m o n c ol d. N E n gl J Me d. 3 3 0( 1): 2 5 – 3 0. 
[ H o d ges L A & H u g hes A & Tar gett D & D urca n M ( 2 0 1 4)] D oes a H ot Dri n k Pr o vi de Faster 
A bs or pti o n of Paraceta m ol T ha n a Ta blet? A P har mac osci nti gra p hic St u d y i n Healt h y Male 
V ol u nteers. P har m Res ( 2 0 1 4) 3 1: 2 0 7 8 – 2 0 8 5. 
[ He n gst ma n n J H, G or o nz y J ( 1 9 8 2)] P har mac o ki netics of H- 3 P he n yle p hri ne i n Ma n. 
E ur o pea n J o ur nal of Cli nical P har mac ol o g y; 2 1 ( 4): 3 3 5- 3 4 1. 
[ Presc ott L. Paraceta m ol (aceta mi n o p he n): a critical bi bli o gra p hic re vie w]. L o n d o n: Ta yl or & 
Fra ncis; 1 9 9 6. 
[ Presc ott L F, Y o o vat ha w or n K, Ma kara na n da K et al,  ( 1 9 9 3)].  I m paire d a bs or pti o n of 
paraceta m ol i n ve getaria ns. Br J Cli n P h ar m ac ol 1 9 9 3; 3 6: 2 3 7- 2 4 0. 
[ Wal d A, T hiel D H V, H oec hstetter et al, ( 1 9 8 1)]. C CI 
 Gastr oi ntesti nal tra nsit: t he effect of 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 51 of 56the menstrual cycle. Gastroenterology 1981; 80:1497-1500.
 [National Council on Radiation Protection and Measurements (NCRP) (1993)]. Limitations 
of Exposure to Ionizing Radiation. NCRP Report No 116, Bethesda, MD; 1993]. NCRP 
Publications ISBN#0-929600-30-4.
[ICRP 103 (2007)] vol. 37, 2-4, 2007
[INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL 
PRACTICE E6(R2)]
T herafl u Da yti me Se vere C ol d & C o u g h P o w der f or Oral S ol uti o n / T herafl u E x press Ma x Da yti me Se vere C ol d a n d C o u g h ca plets 
Pr ot oc ol n u m ber 2 0 8 8 2 1 
Cli nical Pr ot oc ol  v 2. 0, 2 5 Ja n 2 0 1 8 
Gla x o S mit h Kli ne C o ns u mer Healt hcare C o nfi de ntial 
Te m plate Versi o n Effecti ve: 2 2-J u n- 2 0 1 7 
Pa ge 5 2  of 5 6 1 3  A P P E N DI X 
1 3. 1  R A DI A TI O N D O SI M E T R Y 
C CI Ma xi m u m esti mate d ra diati o n d ose t o vari o us or ga ns fr o m t he oral a d mi nistrati o n of t he 
f oll o wi n g: 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285909] that is prepared by [CONTACT_914843]. Example step 
wise procedures are summarized in the following.
Treatment A: Theraflu Solution (will be prepared on visit 2 day 1, maximum 3 hours before 
administration)
Pour the drug powder contents from an individual sachet into a single glass bottle (with 
cap). Confirm transfer of material by [CONTACT_8497].
Heat distilled drinking water to approximately 90-95°C and add 225 mL of the heated 
water to the bottle containing the drug powder (confirm the addition of the 225 mL of 
water by [CONTACT_8497]). Screw the cap onto the bottle and mix to dissolve the contents of the 
sachet. 
Allow the dissolved Theraflu solution to cool to approximately 40-50°C. 
After cooling, a small volume (1 to 10 microliters) of 99mTc-DTPA is added to the 
individual bottles containing the drug solution to achieve a maximum of 108 µCi (4 
MBq) per individual dose at the time of dosing. 
The container is capped, labeled for individual subject use and stored at a temperature 
between 35-45°C until administration.
Treatment B: Theraflu ExpressMax Daytime Severe Cold and Cough Caplet (will be prepared 
up to 18 hours before administration)
Individual caplets are radiolabeled by [CONTACT_914844]-99m DTPA into approximately the 
center portion of the caplet.
The caplet is oblong, approximately 17.8 mm long, 7.4 mm wide, and 6.0 mm thick. 
The caplet weight is approximately 630 mg. One side the caplet is inscribed with 
“1143D” and the opposite side is blank and has no inscription.
The original caplet weight is determined. On the blank side inscribed, a hole, 
approximately 1 mm diameter is drilled to a depth of approximately one-half of the 
caplet’s thickness (~2-2.5 mm deep). After drilling, the caplet is re-weighed.
Tc-99m DTPA (dissolved in saline) is carefully pi[INVESTIGATOR_914816] a low volume 
liquid (approximately 0.5 – 2 microliters) such that the maximum radioactive level does 
not exceed 54 µCi (2 MBq) per individual caplet at the time of dosing. The applied 
liquid is allowed to air dry at room temperature.
The hole is filled with the equivalent powder blend from a crushed caplet. The caplet 
weight is again recorded.
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 54 of 56The surface area of the filled region of the caplet may be sealed with an appropriate 
material if determined to be necessary.
Radiolabeled caplets are packaged as unit doses (2 caplets per container), labeled for 
individual subject use and stored at room temperature until administration.  
The preparation of the radiolabeled doses will be documented in a detailed dose preparation 
record that is prepared by [CONTACT_914843].
13.[ADDRESS_1285910] data collection tool
99mTc-DTPA Technetiu
m-99m-diethylene-triamine-pentaacetate
EC ethics committee
ECG electrocardiogram
EDC Electronic data capture
EDTA edetic acid (ethylenediaminetetraacetic acid)
FDA Food and Drug Administration ([LOCATION_002])
FSFV First subject first visit
FSH follicle-stimulating hormone
GCC Global Clinical Supplies
GCP Good Clinical Practice
GE Gastric emptying
GGT gamma-glutamyl transpeptidase
[COMPANY_004] CH GlaxoSmithKline Consumer Health
[COMPANY_004] CPL GlaxoSmithKline Clinical Pharmacologist 
Theraflu Daytime Severe Cold & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-2017
Page 55 of 56Abbreviation Term
hCG human chorionic gonadotropin
HDL-C high density lipoprotein cholesterol
HIV human immunodeficiency virus
HIV-Ab Human Immunodeficiency Virus antibody
HCV-Ab Antibodies Hepatitis C Virus
HBcAg Core antigen of Hepatitis B
HBsAg Surface antigen of Hepatitis B
IB investigator’s brochure
ICH International Conference on Harmonisation
IHV InVentiv Health Care
ID identification
INR international normalized ratio
IRB institutional review board
IRC internal review committee
IUD intrauterine device
IUS Intrauterine system
K2EDTA dipotassium ethylene diamine tetraacetic acid
LDL-C low density lipoprotein-cholesterol
LFT liver function test
LSLV last subject last visit 
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA medical Dictionary for Regulatory Activities
mSv mill
isievert 
N/A not applicable
NCRP national council on radiation protection
PI [INVESTIGATOR_914817]
n equivalent man 
RNA ribonucleic acid
RR Respi[INVESTIGATOR_914818] & Cough Powder for Oral Solution / Theraflu ExpressMax Daytime Severe Cold and Cough caplets
Protocol number 208821 
Clinical Protocol  v2.0, 25 Jan 2018
GlaxoSmithKline Consumer Healthcare Confidential
Template Version Effective: 22-Jun-[ADDRESS_1285911] operating procedure
SS safety statement
T1/[ADDRESS_1285912] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_605513]